Other mutations are currently under investigation, such as NTRK fusion (<1% of CRC) or the KRAS G12C mutation (3% of mCRC), both targetable by the new drugs entrectinib and sotorasib, respectively [18,19]. This evidence concerns the gene KRAS and colorectal carcinoma.